New Research: 416 Million People at Risk of Developing Alzheimer’s Disease Globally
A new study published by PAVE in Alzheimer's & Dementia: The Journal of the Alzheimer's Association highlights prevalence of Alzheimer’s disease across disease stages. Findings suggest that a majority of patients are asymptomatic or preclinical, and new strategies for the prevention of Alzheimer’s disease could benefit millions of people over the age of 50.
PAVE Research: “Estimates of Current Capacity for Diagnosing Alzheimer’s Disease in Sweden and the Need to Expand Specialist Numbers”
This study assesses Sweden's current capacity to diagnose patients eligible for disease-modifying AD treatment in a timely manner and estimates the investment needed to reduce wait times to a target of less than six months.
PAVE HTA Toolkit: A Guide to Patient Engagement in Alzheimer’s Treatment Access (2025)
This toolkit explains how Health Technology Assessment (HTA) works across Europe and provides guidance for patients, caregivers, and advocacy groups to participate meaningfully at each stage of the process. It equips the Alzheimer’s community with the knowledge to share lived experience, contribute evidence, and strengthen advocacy efforts.